Given the clinical benefits of CD38-based anti-MM therapies, efforts have been made to upregulate its expression on plasma cells surface as a strategy to make results even more compelling [29,30,31,32,33,34,35]. This evidence concerns the gene CD38 and Miyoshi myopathy.